The Conversation (0)
Seeking Alpha contributor Point of Return profiled medical device company Miraculins Inc. (TSXV:MOM) and its Scout DS® diabetes screening device. The author, who owns shares in the company, points out that the device is the only one of its kind that is not invasive and delivers immediate results at point of care.
As quoted in the publication:
Bottom line, I think that there is a very compelling investment opportunity given: (1) the opportunity to start generating revenues over the next 6 months; (2) the significance of forthcoming news releases to act as catalysts to unlock shareholder value; (3) the market opportunity preventing diabetes and coronary artery disease is very attractive; (4) there has been between $40-$50 million already invested into the Scout DS®; and (5) the Scout DS® is so novel there are no direct competitors, and its business model is tried and true.